Innate Pharma (IPHA) Change in Working Capital (2019 - 2025)
Innate Pharma's (IPHA) quarterly Change in Working Capital came in at -$2328.1 in Q4 2025, down 109.08% YoY from $25646.3 in Q4 2024, and down 109.08% on a QoQ basis from $25646.3 in Q4 2024.
Innate Pharma (IPHA) Change in Working Capital (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Change in Working Capital data on file, last reported at -$2328.1 in Q4 2025.
- Quarterly Change in Working Capital fell 109.08% year-over-year to -$2328.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45077.6 (up 657.8% YoY) and the FY2025 annual result came in at $12.4 million, up 129.57% from the prior year.
- Change in Working Capital slipped to -$2328.1 in Q4 2025, from $25646.3 in the prior quarter.
- In the past five years, Change in Working Capital ranged from a high of $25646.3 in Q4 2024 to a low of -$1.8 million in Q2 2021.
- A 5-year average of -$449074.2 and a median of -$2328.1 in 2025 frame the typical range for Change in Working Capital.
- Annual changes were most pronounced in 2021 — Change in Working Capital plunged 347.63% — and 2024, when it soared 297.27%.
- Tracing IPHA's Change in Working Capital over 5 years: stood at -$1.4 million in 2021, then soared by 101.13% to $15303.7 in 2022, then sank by 57.82% to $6455.6 in 2023, then soared by 297.27% to $25646.3 in 2024, then sank by 109.08% to -$2328.1 in 2025.
- The last three Change in Working Capital figures came in at -$2328.1 (Q4 2025), $25646.3 (Q4 2024), and $6455.6 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -49.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,328.09 |
| Dec 31, 2025 | -2,328.09 |
| Dec 31, 2024 | 25,646.29 |
| Dec 31, 2024 | 25,646.29 |
| Dec 31, 2023 | 6,455.64 |
| Dec 31, 2023 | 6,455.64 |
| Dec 31, 2022 | 15,303.71 |
| Dec 31, 2022 | 15,303.71 |
| Jun 30, 2022 | -55,486.95 |
| Jun 30, 2022 | -55,486.95 |
| Dec 31, 2021 | -1.36 Mn |
| Dec 31, 2021 | -1.36 Mn |
| Jun 30, 2021 | -1.78 Mn |
| Jun 30, 2021 | -1.78 Mn |
| Dec 31, 2020 | -302,841.62 |
| Dec 31, 2020 | -302,841.62 |
| Jun 30, 2020 | -410,844.63 |
| Jun 30, 2020 | -410,844.63 |
| Dec 31, 2019 | 608,788.22 |
| Dec 31, 2019 | 608,788.22 |